# US 2015/0148735 A1 · Electric-Field Assisted Administration of Tapentadol

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0148735 A1
- Document ID: US20150148735A1
- Status: Published application
- Kind: A1
- Application number: 14/598,650
- Filed: 2015-01-16
- Published: 2015-05-28
- Earliest claimed: 2012-07-20
- Assignees: Gruenenthal GmbH
- Applicants: Gruenenthal GmbH
- Inventors: Ingo FRIEDRICH; Martin MIKYNA; Sandra GEDAT; Richard GUY
- Web page: https://patentgrep.com/patent/US20150148735A1

## CPC

- A61K 41/0047: {Sonopheresis, i.e. ultrasonically-enhanced transdermal delivery, electroporation of a pharmacologically active agent}
- A61K 9/0009: {involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis}
- A61K 9/06: Ointments; Bases therefor; {Other semi-solid forms, e.g. creams, sticks, gels (composition of ointments, creams or gels A61K47/00)}
- A61K 9/703: {characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches}
- A61K 9/7084: {Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches}
- A61K 31/135: having aromatic rings {, e.g. ketamine, nortriptyline (methadone A61K31/137)}
- A61K 47/38: Cellulose; Derivatives thereof
- A61N 1/0412: {Specially adapted for transcutaneous electroporation, e.g. including drug reservoirs}
- A61N 1/0448: {Drug reservoir}
- A61N 1/30: Apparatus for iontophoresis, {i.e. transfer of media in ionic state by an electromotoric force into the body}, or cataphoresis
- A61N 1/303: {Constructional details (electrodes for external use A61N1/0428)}
- F04C 2270/0421: Controlled or regulated
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61N: ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY (measurement of bioelectric currents A61B; surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body A61B18/00; anaesthetic apparatus in general A61M; incandescent lamps H01K; infrared radiators for heating H05B)
- F04C: ROTARY-PISTON, OR OSCILLATING-PISTON, POSITIVE-DISPLACEMENT MACHINES FOR LIQUIDS (engines F03C); ROTARY-PISTON, OR OSCILLATING-PISTON, POSITIVE-DISPLACEMENT PUMPS

## Abstract

A pharmaceutical device for electric-field assisted administration of Tapentadol and/or of a physiologically acceptable salt thereof, the device comprising at least one pair of electrodes consisting of an active electrode and a counter electrode (1a and 2a and/or 1b and 2b), optionally at least one additional electrode as an auxiliary electrode, at least one drug reservoir (3) containing at least a portion of the Tapentadol and/or a physiologically acceptable salt thereof, and means (4) for applying the device to skin (5).

## Claims

### Claim 1

A pharmaceutical device for electric-field assisted administration of Tapentadol and/or of a physiologically acceptable salt thereof, the device comprising
at least one pair of electrodes consisting of an active electrode and a counter electrode (1a and 2a and/or 1b and 2b),
optionally at least one additional electrode as an auxiliary electrode,
at least one drug reservoir (3) containing at least a portion of the Tapentadol and/or a physiologically acceptable salt thereof, and
means (4) for applying the device to skin (5).

### Claim 2 (depends on 1)

The device according to claim 1, wherein the pair of electrodes (1a and 2a) is provided to create an electric field (Fa) by applying an electrical potential difference (Va), and is arranged such that the electric field (Fa) is substantially perpendicular to the skin (5) when the device is applied thereto.

### Claim 3 (depends on 2)

The device according to claim 2, wherein the electric field (Fa) induces electrophoretic movement of the Tapentadol and/or of the physiologically acceptable salt thereof within the device from the drug reservoir (3) towards the skin (5).

### Claim 4 (depends on 1)

The device according to claim 1, wherein the pair of electrodes (1b and 2b) is provided to create an electric field (Fb) by applying an electrical potential difference (Vb), and is arranged such that the electric field (Fb) is substantially parallel to the skin (5) when the device is applied thereto.

### Claim 5 (depends on 4)

The device according to claim 4, wherein the electric field (Fb) induces iontophoretic movement of the Tapentadol and/or of the physiologically acceptable salt thereof out of the device from the drug reservoir (3) into the skin (5).

### Claim 6 (depends on 1)

The device according to claim 1 comprising
A) at least one first pair of electrodes consisting of an active electrode and a counter electrode (1a and 2a), which are provided to create an electric field (Fa) by applying an electrical potential difference (Va), and are arranged such that the electric field (Fa) is substantially perpendicular to the skin (5) when the device is applied thereto, and
at least one additional electrode as an auxiliary electrode, which functions as a counter electrode (2b) in such a way that the counter electrode (2a) of the first pair of electrodes (1a and 2a) is used as an active electrode (1b) for creating an electric field (Fb) by applying an electrical potential difference (Vb), these two electrodes forming a second pair of electrodes consisting of an active electrode and a counter electrode (1b and 2b) and are arranged such that the electric field (Fb) is substantially parallel to the skin (5) when the device is applied thereto,
or
B) at least one first pair of electrodes consisting of an active electrode and a counter electrode (1b and 2b), which are provided to create an electric field (Fb) by applying an electrical potential difference (Vb), and are arranged such that the electric field (Fb) is substantially parallel to the skin (5) when the device is applied thereto, and at least one additional electrode as an auxiliary electrode, which functions as an active electrode (1a) for creating an electric field (Fa) by applying an electrical potential difference (Va) using the active electrode (1b) of the first pair of electrodes (1b and 2b) as a counter electrode (2a), these two electrodes forming a second pair of electrodes consisting of an active electrode and a counter electrode (1a and 2a) and are arranged such that the electric field (Fa) is substantially perpendicular to the skin (5) when the device is applied thereto.

### Claim 7 (depends on 6)

The device according to claim 6, wherein
A) the electric field (Fa) created by the first pair of electrodes consisting of an active electrode and a counter electrode (1a and 2a) induces electrophoretic movement of the Tapentadol and/or of the physiologically acceptable salt thereof within the device from the drug reservoir (3) towards the skin (5) and the electric field (Fb) created by the second pair of electrodes consisting of an active electrode and a counter electrode (1b and 2b) induces iontophoretic movement of the Tapentadol and/or of the physiologically acceptable salt thereof out of the device from the drug reservoir (3) into the skin (5),
or
B) the electric field (Fb) created by the first pair of electrodes consisting of an active electrode and a counter electrode (1b and 2b) induces iontophoretic movement of the Tapentadol and/or of the physiologically acceptable salt thereof out of the device from the drug reservoir (3) into the skin (5) and
the electric field (Fa) created by the second pair of electrodes consisting of an active electrode and a counter electrode (1a and 2a) induces electrophoretic movement of the Tapentadol and/or of the physiologically acceptable salt thereof within the device from the drug reservoir (3) towards the skin (5).

### Claim 8 (depends on 1)

The device according to claim 1 additionally comprising a control unit for regulating an electrical potential difference (Va and/or Vb) applied to the pair(s) of electrodes (1a and 2a and/or 1b and 2b) and/or the optionally present additional auxiliary electrode.

### Claim 9 (depends on 1)

The device according to claim 1, wherein the drug reservoir (3) comprises an aqueous medium, preferably a hydrogel.

### Claim 10 (depends on 1)

The device according to claim 1, wherein the drug reservoir (3) contains Tapentadol in form of a physiologically acceptable salt thereof.

### Claim 11 (depends on 1)

The device according to claim 1, which is a pharmaceutical patch comprising a surface layer (7) and an adhesive layer (4a) and wherein the drug reservoir (3) is preferably located between the surface layer (7) and the adhesive layer (4a) or preferably located at least partly within the adhesive layer (4a).

### Claim 12 (depends on 1)

Tapentadol and/or a physiologically acceptable salt thereof for use in the treatment of pain, wherein the Tapentadol and/or the physiologically acceptable salt thereof is administered by means of a pharmaceutical device according to claim 1.

### Claim 13 (depends on 12)

Tapentadol and/or a physiologically acceptable salt thereof for use according to claim 12, wherein an electrical potential difference (Va and/or Vb) is applied to the at least one pair of electrodes consisting of an active electrode and a counter electrode (1a and 2a and/or 1b and 2b), and/or the optionally present at least one additional electrode, which is within the range of from 0.5 to 12.5 V.

### Claim 14 (depends on 12)

Tapentadol and/or a physiologically acceptable salt thereof for use according to claim 12, wherein an electrical potential difference (Va and/or Vb) is repeatedly applied in predetermined repetition intervals in each case for a predetermined period of time within the total period of time, during which the device is applied to the skin (5).

### Claim 15 (depends on 12)

Tapentadol and/or a physiologically acceptable salt thereof for use according to claim 12, wherein the total period of time during which an electrical potential difference (Va and/or Vb) is applied to the pair of electrodes (1a and 2a and/or 1b and 2b) and/or optionally to the additional auxiliary electrode is at most 75% of the total period of time during which the device is applied to the skin (5).
